摘要
目的探讨ArcherQA三维剂量独立验证系统在鼻咽癌调强放疗计划验证中的可行性。方法回顾性选取Eclipse治疗计划系统(TPS)制定的105例鼻咽癌患者调强放疗计划,分别利用ArcherQA与Portal dosimetry(PD)验证系统进行剂量验证。比较ArcherQA与PD的γ通过率(3 mm/3%,TH=10%),以及ArcherQA与TPS在靶区剂量(D_(mean))、D_(90%))与危及器官剂量(D_(mean))上的差异,并分析ArcherQA结果中各危及器官的三维γ通过率情况。结果ArcherQA计算得到的平均三维γ通过率为(99.04±1.01)%,PD测量结果的平均二维γ通过率为(99.49±0.78)%,二者差异具有统计学意义(t=-3.35,P<0.05)。ArcherQA与TPS在靶区的剂量学差异为:GTV:D_(mean)(0.57±0.48)%,D_(90%)(0.65±0.56)%;平均γ通过率:GTV(97.67±3.43)%,GTVnd-L(97.80±4.35)%,GTVnd-R(97.82±4.07)%,CTV1(97.88±2.44)%,CTV2(96.64±4.32)%;各靶区平均剂量差异为CTV1(0.57±0.46)%,GTVnd-L(0.85±0.55)%,GTVnd-R(0.73±0.55)%,CTV2(0.88±0.52)%;ArcherQA结果中各危及器官的平均γ通过率为脑干(99.93±0.22)%,视交叉(99.17±2.82)%,眼晶状体(100±0)%,脊髓(99.56±1.05)%,甲状腺(99.00±2.06)%,气管(87.86±10.42)%。各危及器官平均剂量,除左侧视神经、右侧海马、右侧腮腺外,差异均具有统计学意义(t=-14.62~4.82,P<0.05)。结论ArcherQA基于高性能图形处理器平台,采用高精度蒙特卡罗算法,可根据患者CT图像快速并准确地计算出体内的三维剂量分布和γ通过率,并给出各感兴趣区域的剂量-体积直方图(DVH)指标参数比较,可用于鼻咽癌调强放疗计划验证,不占用加速器机时,有利于提高工作效率。
Objective To investigate the feasibility of applying the ArcherQA three-dimensional(3D)dosimetric verification system in intensity-modulated radiotherapy(IMRT)plans for nasopharyngeal carcinoma(NPC).Methods A retrospective analysis was conducted for 105 NPC patients′IMRT plans developed using the Eclipse treatment planning system(TPS).Dose verification was conducted using the ArcherQA system and through portal dosimetry(PD).Moreover,this study comparedγpassing rates(criteria:3 mm/3%,TH=10%)between ArcherQA and PD and the doses delivered to the target volume(D_(mean),D_(90%))and organs at risk(OARs)(D_(mean))between ArcherQA and TPS,and analyzed the 3Dγpassing rates of each organ at risk calculated by ArcherQA.Results The average 3Dγpassing rate calculated by ArcherQA was(99.04±1.01)%,and the average 2Dγpassing rate measured by PD was(99.49±0.78)%,with statistically significant differences(t=-3.35,P<0.05).The dosimetric differences to the target volume between ArcherQA and TPS were as follows:the average difference in D_(mean)to the gross tumor volume(GTV)was(0.57±0.48)%,and the average difference in D_(90%)was(0.65±0.56)%.For the target volume,the averageγpassing rate was(97.67±3.43)%for GTV,(97.80±4.35)%for GTVnd-L,(97.82±4.07)%for GTVnd-R,(97.88±2.44)%for CTV1,and(96.64±4.32)%for CTV2.The_(mean)dose difference of each target volume was CTV1(0.57±0.46)%,GTVnd-L(0.85±0.55)%,GTVnd-R(0.73±0.55)%,and CTV2(0.88±0.52)%.For OARs,the_(mean)γpassing rate was(99.93±0.22)%for the brainstem,(99.17±2.82)%for the optic chiasm,(100±0)%for the lens,(99.56±1.05)%for the spinal cord,(99.00±2.06)%for the thyroid,and(87.86±10.42)%for the trachea.Statistically significant differences in the average doses to OARs were observed(t=-14.62 to 4.82,P<0.05),except for those to the left optic nerve,the right hippocampus,and the right parotid gland.Conclusions Based on the high-performance GPU platform and the Monte Carlo dose algorithm,ArcherQA can provide accurate 3D dose distribution and 3Dγpassing rates inside
作者
王鹏辉
宫帅
丁寿亮
阳露
王勐
裴曦
黄晓延
刘红冬
Wang Penghui;Gong Shuai;Ding Shouliang;Yang Lu;Wang Meng;Pei Xi;Huang Xiaoyan;Liu Hongdong(Radiotherapy Center,Qingdao Municipal Hospital Affiliated to Qingdao University Medical College,Qingdao 266011,China;State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Department of Radiation Oncology of Sun Yat-sen University Cancer Center,Guangzhou 510060,China;Radiotherapy Center,Affiliated Tumor Hospital of Guangzhou Medical University,Guangzhou 510095,China;Nuclear Medical Physics Institute,University of Science and Technology of China,Hefei 210027,China)
出处
《中华放射医学与防护杂志》
CAS
CSCD
北大核心
2022年第8期598-604,共7页
Chinese Journal of Radiological Medicine and Protection
基金
国家自然科学基金(11805292)
广东省自然科学基金(2018A0303100020)
广东省基础与应用基础粤穗联合青年基金(2021A1515110642)
中华国际医学交流基金会肿瘤精准放疗星火计划(2019-N-11-34)。
